Fritextsökning
Artiklar per år
Innehållstyper
-
The winner of the race
She learned how to work hard at an early age and her devotion has certainly paid off. Whether it is field running or running a company, the key to success is focus according to Yvonne Mårtensson.
-
With their hands on the legal levers
It is wonderful news for the Scandinavian scientific community. At the end of May it stood clear that Lund will host to the European Spallation Source.
-
Dags igen för världens största branschmöte
Den 18 maj slogs portarna upp for BIO2009 i Atlanta, Georgia. På agendan för de 15 000 besökarna stog bland annat Elton John och ett svenskt stamcellsseminarium.
-
Koldioxidinkubatorer baserade på innovativ teknologi
Galaxy är en ny förbättrad serie koldioxidinkubatorer från New Brunswick Scientific.
-
Ex-diplomat ska leda Navamedic
Han har tidigare varit svensk toppdiplomat i Indien. Nu tar han över rodret i det norska specialty pharmabolaget.
-
Astrazeneca i patentstrid
En generisk version av Pulmicort har godkänts för försäljning i USA. Patentintrång, hävdar Astrazeneca och stämmer nu bolaget bakom ansökan.
-
Astrachef blir hedersdoktor
En av de tre nya hedersdoktorerna vid KI är en av Sveriges tyngsta näringslivsprofiler.
-
Major changes to the Q-Med board
The nomination committee wants to replace half of the existing board, including the current Chairman. An Extraordinary General Meeting will take place on February 4.
-
Swedish top scientists to EMBO
Two Swedish top scientists will have a really good chance to influence European life science research from now on. One is from the Karolinska Institutet, and one is from the University of Uppsala.
-
Faster sales but less profits for Probi
The probiotic company increases its turnover, and the net results are twice as large as last year.
-
Symphogen buys tumor blocking technology
The seller is a pioneer in developing ligand traps to treat cancer and other diseases. "An excellent fit with our scientific and strategic focus," said Kirsten Drejer, CEO of Symphogen. Ph.D.
-
First ever study of human stem cell treatment
The FDA says yes to the world's first study in man of a human embryonic stem cell based therapy to treat spinal injury.
-
Re-painting the big pig-ture
Why do tame pigs show such variety in colouring, when their wild relatives are so plain? Swedish researchers know who is to blame. But the big question is why.
-
Go ahead for leg wound study
Tripep starts a phase II-study of their wound healing joint venture project.
-
Athera signs production partnership
The companys novel cardiovascular product will be manufactured in Germany.
-
Test if you carry the fat virus
In a soon future there may be a quick and simple test that could show if you are infected with Ad-36, a human adenovirus that can make you over-weight.
-
New study of toxins and heart disease
Is there a correlation between exposure to hormone interfering environmental toxins and increased risk of developing cardiovascular disease? A new patient study will try to evaluate this, and one thousand people are to be included.
-
Pfizer lays a chunky bid on Wyeth
The merger of two pharma giants is the largest industry deal so far this year. Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at approximately $68 billion. The Boards of Directors of both companies have said yes to the deal that may lead to lay-offs of some 8,000 persons.
-
New CEO to Promedvi
Sigrun Axelsson has taken on the leadership of the Lund-based medtech company.
-
New member to Active board
The Election Committee of Active Biotech proposes a very experienced financial sector executive to join the company board. Five existing members are also to be re-elected at the AGM in May.
-
A smart company takes care of its best
Lundbeck didn't have to look far to find it's new international Director of Marketing. The talent was already in the house.
-
Less scars with new product
A new Swedish product for post surgical scar formation enters clinical development.
-
Researchers goes to the bottom of the brain
Swedish researchers have recently got new and deeper knowledge about the smallest part of the brain, the granule cells.
-
EUR 2 million for peanut allergies
ALK Abelló has signed an agreement to invest EUR 2 million in the French biotechnology company DBV Technologies.
BREAKING